Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients.

ABSTRACT:

Background

For advanced non-small cell lung cancer patients with the epidermal growth factor receptor L858R mutation, the efficacy of the combination of tyrosine kinase inhibitor (TKI) and chemotherapy is suboptimal. Currently, it is unclear whether the combination of bevacizumab, gefitinib, and chemotherapy could improve the survival.

Materials and methods

Data was retrospectively collected at Shandong Provincial Hospital between June 2019 and December 2022. The patients were divided into two groups, ATC group receiving bevacizumab, gefitinib, and chemotherapy, and TC group receiving gefitinib and chemotherapy. After propensity score matching (PSM), progression-free survival (PFS) and overall survival (OS) were calculated along with the objective response rate (ORR) and dis

SUBMITTER: Lei L 

PROVIDER: S-EPMC12541177 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature